U.S. investigative panel to look into drug pricing next year

By Sarah N. Lynch WASHINGTON (Reuters) – A U.S. House of Representatives investigative panel said it plans to hold a 2016 hearing on skyrocketing drug costs, a move that comes at a time when Valeant Pharmaceuticals International is facing increased scrutiny into its pricing practices. A spokeswoman for the U.S. House Committee on Oversight & Government Reform said on Monday the panel is conducting a thorough investigation into drug pricing and has reached out to drug companies to gather information. Earlier this month, the U.S. Senate Special Committee on Aging launched a new probe into drug pricing at Valeant and Turing, signaling growing bipartisan agreement on the need to review the rising cost of prescription drugs in the United States.

Original post: 
U.S. investigative panel to look into drug pricing next year